文献速递新生儿儿童神经与发育行为

新生儿脑病严重程度与神经发育结局的血浆及脑脊液候选生物标志物

Plasma and Cerebrospinal Fluid Candidate Biomarkers of Neonatal Encephalopathy Severity and Neurodevelopmental Outcomes.
PubMed 文献 · J Pediatr · 2020-06-28

该回顾性队列研究检测了足月新生儿脑病患儿血浆(N=155,生后0-1天)和脑脊液(n=30,生后0-7天)中中枢神经系统坏死、炎症及营养性蛋白标志物,并与健康足月新生儿(N=30)比较。结果显示血浆tau、GFAP、NRGN与脑病分级直接相关,BDNF呈负相关;血浆tau与MRI异常直接相关,且与15-30月龄Bayley认知和运动结局负相关;脑脊液NRGN、GFAP、IL-6、IL-10、IL-8与神经发育结局负相关。结论认为血浆候选生物标志物可预测脑病严重程度、惊厥、MRI异常及15-30月龄神经发育结局。

要点

  • 血浆tau、GFAP、NRGN与新生儿脑病分级直接相关,BDNF呈负相关。
  • 血浆tau与MRI异常直接相关,与15-30月龄Bayley认知和运动结局负相关。
  • 脑脊液NRGN、GFAP、IL-6、IL-10、IL-8与神经发育结局负相关,但与脑病分级、惊厥或MRI异常无显著关系。

核心结论

  • 血浆候选生物标志物可预测新生儿脑病严重程度、惊厥、MRI异常及15-30月龄神经发育结局。

研究设计与样本

  • 回顾性队列研究,纳入新生儿脑病患儿血浆样本N=155(生后0-1天)和脑脊液样本n=30(生后0-7天),以及健康足月新生儿N=30(≥36周胎龄)作为对照。
  • 检测中枢神经系统坏死标志物(GFAP、NRGN、tau)、炎症标志物(IL-6、IL-8、IL-10)和营养性蛋白(BDNF、VEGF)。
  • 临床结局包括Sarnat脑病评分、惊厥、MRI评分及15-30月龄Bayley婴幼儿发育量表III。

主要发现

  • 新生儿脑病患儿血浆NRGN、tau、IL-6、IL-8、IL-10高于对照,BDNF和VEGF低于对照。
  • 血浆tau、GFAP、NRGN与脑病分级直接相关,BDNF与脑病分级呈负相关。
  • 血浆IL-6与惊厥呈负相关,血浆tau与MRI异常直接相关。
  • 血浆tau与15-30月龄Bayley认知和运动结局负相关。
  • 脑脊液NRGN与认知、运动、语言结局负相关;GFAP、IL-6、IL-10与认知和运动结局负相关;IL-8与运动结局负相关;脑脊液标志物与脑病分级、惊厥、MRI异常无显著关系。

临床怎么用

  • 血浆tau、GFAP、NRGN、BDNF等候选标志物可用于辅助评估新生儿脑病严重程度及远期神经发育风险。
  • 脑脊液标志物与神经发育结局相关,但本研究样本量有限,暂不宜作为常规临床决策依据。

局限性

  • 本研究为回顾性队列研究,脑脊液样本量较小(n=30)。
  • 生物标志物与结局的关联性需在前瞻性研究中进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To identify candidate biomarkers in both plasma and cerebrospinal fluid (CSF) that are associated with neonatal encephalopathy severity measured by encephalopathy grade, seizures, brain injury by magnetic resonance imaging (MRI), and neurodevelopmental outcomes at 15-30 months. STUDY DESIGN: A retrospective cohort study of plasma (N = 155, day of life 0-1) and CSF (n = 30, day of life 0-7) from neonates with neonatal encephalopathy and healthy neonates born at term (N = 30, ≥36 weeks of gestation) was conducted. We measured central nervous system necrosis (glial fibrillary acidic protein [GFAP], neurogranin [NRGN], tau), inflammatory (interleukin [IL]-6, IL-8, IL-10), and trophic (brain-derived neurotrophic factor [BDNF], vascular endothelial growth factor) proteins. Clinical outcomes were Sarnat scores of encephalopathy, seizures, MRI scores, and Bayley Scales of Infant and Toddler Development III at 15-30 months. RESULTS: Plasma NRGN, tau, IL-6, IL-8, and IL-10 were greater, whereas BDNF and vascular endothelial growth factor were lower in patients with neonatal encephalopathy vs controls. In plasma, tau, GFAP, and NRGN were directly and BDNF inversely associated with encephalopathy grade. IL-6 was inversely related to seizures. Tau was directly related to MRI abnormalities. Tau was inversely associated with Bayley Scales of Infant and Toddler Development III cognitive and motor outcomes. In CSF, NRGN was inversely associated with cognitive, motor, and language measures. GFAP, IL-6, and IL-10 were inversely related to cognitive and motor outcomes. IL-8 was inversely related to motor outcomes. CSF candidate biomarkers showed no significant relationships with encephalopathy grade, seizures, or MRI abnormalities. CONCLUSIONS: Plasma candidate biomarkers predicted encephalopathy severity, seizures, MRI abnormalities, and neurodevelopmental outcomes at 15-30 months.

来源:J Pediatr,查看原文。版权归原作者所有。

引用

  1. Dietrick B, Molloy E, Massaro AN, et al. Plasma and Cerebrospinal Fluid Candidate Biomarkers of Neonatal Encephalopathy Severity and Neurodevelopmental Outcomes. J Pediatr. 2020. PMID: 32610169. doi:10.1016/j.jpeds.2020.06.078

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。